Combination therapy with anti-PD-1, anti-TIM-3, and focal radiation results in regression of murine gliomas

Jennifer E. Kim, Mira A. Patel, Antonella Mangraviti, Eileen S. Kim, Debebe Theodros, Esteban Velarde, Ann Liu, Eric W. Sankey, Ada Tam, Haiying Xu, Dimitrios Mathios, Christopher M. Jackson, Sarah Harris-Bookman, Tomas Garzon-Muvdi, Mary Sheu, Allison M. Martin, Betty M. Tyler, Phuoc T. Tran, Xiaobu Ye, Alessandro Olivi & 6 others Janis M. Taube, Peter C. Burger, Charles G. Drake, Henry Brem, Drew M. Pardoll, Michael Lim

Research output: Research - peer-reviewArticle

Abstract

Purpose: Checkpoint molecules like programmed death-1 (PD-1) and T-cell immunoglobulin mucin-3 (TIM-3) are negative immune regulators that may be upregulated in the setting of glioblastoma multiforme. Combined PD-1 blockade and stereotactic radiosurgery (SRS) have been shown to improve antitumor immunity and produce long-term survivors in a murine glioma model. However, tumor-infiltrating lymphocytes (TIL) can express multiple checkpoints, and expression of ≥2 checkpoints corresponds to a more exhausted T-cell phenotype. We investigate TIM-3 expression in a glioma model and the antitumor efficacy of TIM-3 blockade alone and in combination with anti-PD-1 and SRS. Experimental Design: C57BL/6 mice were implanted with murine glioma cell line GL261-luc2 and randomized into 8 treatment arms: (i) control, (ii) SRS, (iii) anti-PD-1 antibody, (iv) anti-TIM-3 antibody, (v) anti-PD-1 + SRS, (vi) anti-TIM-3 + SRS, (vii) anti-PD-1 + anti-TIM-3, and (viii) anti-PD-1 + anti-TIM-3 + SRS. Survival and immune activation were assessed. Results: Dual therapy with anti-TIM-3 antibody + SRS or anti-TIM-3 + anti-PD-1 improved survival compared with anti-TIM-3 antibody alone. Triple therapy resulted in 100% overall survival (P < 0.05), a significant improvement compared with other arms. Long-term survivors demonstrated increased immune cell infiltration and activity and immune memory. Finally, positive staining for TIM-3 was detected in 7 of 8 human GBM samples. Conclusions: This is the first preclinical investigation on the effects of dual PD-1 and TIM-3 blockade with radiation. We also demonstrate the presence of TIM-3 in human glioblastoma multiforme and provide preclinical evidence for a novel treatment combination that can potentially result in long-term glioma survival and constitutes a novel immunotherapeutic strategy for the treatment of glioblastoma multiforme.

LanguageEnglish (US)
Pages124-136
Number of pages13
JournalClinical Cancer Research
Volume23
Issue number1
DOIs
StatePublished - Jan 1 2017

Fingerprint

Mucin-3
Glioma
Immunoglobulins
Radiation
T-Lymphocytes
Therapeutics
Thomsen-Friedenreich antibodies
Radiosurgery
Survival
Glioblastoma
Antibodies
Survivors
Tumor-Infiltrating Lymphocytes
Inbred C57BL Mouse
Anti-Idiotypic Antibodies
Immunity
Research Design
Staining and Labeling
Phenotype
Cell Line

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Combination therapy with anti-PD-1, anti-TIM-3, and focal radiation results in regression of murine gliomas. / Kim, Jennifer E.; Patel, Mira A.; Mangraviti, Antonella; Kim, Eileen S.; Theodros, Debebe; Velarde, Esteban; Liu, Ann; Sankey, Eric W.; Tam, Ada; Xu, Haiying; Mathios, Dimitrios; Jackson, Christopher M.; Harris-Bookman, Sarah; Garzon-Muvdi, Tomas; Sheu, Mary; Martin, Allison M.; Tyler, Betty M.; Tran, Phuoc T.; Ye, Xiaobu; Olivi, Alessandro; Taube, Janis M.; Burger, Peter C.; Drake, Charles G.; Brem, Henry; Pardoll, Drew M.; Lim, Michael.

In: Clinical Cancer Research, Vol. 23, No. 1, 01.01.2017, p. 124-136.

Research output: Research - peer-reviewArticle

Kim, JE, Patel, MA, Mangraviti, A, Kim, ES, Theodros, D, Velarde, E, Liu, A, Sankey, EW, Tam, A, Xu, H, Mathios, D, Jackson, CM, Harris-Bookman, S, Garzon-Muvdi, T, Sheu, M, Martin, AM, Tyler, BM, Tran, PT, Ye, X, Olivi, A, Taube, JM, Burger, PC, Drake, CG, Brem, H, Pardoll, DM & Lim, M 2017, 'Combination therapy with anti-PD-1, anti-TIM-3, and focal radiation results in regression of murine gliomas' Clinical Cancer Research, vol 23, no. 1, pp. 124-136. DOI: 10.1158/1078-0432.CCR-15-1535
Kim JE, Patel MA, Mangraviti A, Kim ES, Theodros D, Velarde E et al. Combination therapy with anti-PD-1, anti-TIM-3, and focal radiation results in regression of murine gliomas. Clinical Cancer Research. 2017 Jan 1;23(1):124-136. Available from, DOI: 10.1158/1078-0432.CCR-15-1535
Kim, Jennifer E. ; Patel, Mira A. ; Mangraviti, Antonella ; Kim, Eileen S. ; Theodros, Debebe ; Velarde, Esteban ; Liu, Ann ; Sankey, Eric W. ; Tam, Ada ; Xu, Haiying ; Mathios, Dimitrios ; Jackson, Christopher M. ; Harris-Bookman, Sarah ; Garzon-Muvdi, Tomas ; Sheu, Mary ; Martin, Allison M. ; Tyler, Betty M. ; Tran, Phuoc T. ; Ye, Xiaobu ; Olivi, Alessandro ; Taube, Janis M. ; Burger, Peter C. ; Drake, Charles G. ; Brem, Henry ; Pardoll, Drew M. ; Lim, Michael. / Combination therapy with anti-PD-1, anti-TIM-3, and focal radiation results in regression of murine gliomas. In: Clinical Cancer Research. 2017 ; Vol. 23, No. 1. pp. 124-136
@article{6de664a1977c4354b500256ada396068,
title = "Combination therapy with anti-PD-1, anti-TIM-3, and focal radiation results in regression of murine gliomas",
abstract = "Purpose: Checkpoint molecules like programmed death-1 (PD-1) and T-cell immunoglobulin mucin-3 (TIM-3) are negative immune regulators that may be upregulated in the setting of glioblastoma multiforme. Combined PD-1 blockade and stereotactic radiosurgery (SRS) have been shown to improve antitumor immunity and produce long-term survivors in a murine glioma model. However, tumor-infiltrating lymphocytes (TIL) can express multiple checkpoints, and expression of ≥2 checkpoints corresponds to a more exhausted T-cell phenotype. We investigate TIM-3 expression in a glioma model and the antitumor efficacy of TIM-3 blockade alone and in combination with anti-PD-1 and SRS. Experimental Design: C57BL/6 mice were implanted with murine glioma cell line GL261-luc2 and randomized into 8 treatment arms: (i) control, (ii) SRS, (iii) anti-PD-1 antibody, (iv) anti-TIM-3 antibody, (v) anti-PD-1 + SRS, (vi) anti-TIM-3 + SRS, (vii) anti-PD-1 + anti-TIM-3, and (viii) anti-PD-1 + anti-TIM-3 + SRS. Survival and immune activation were assessed. Results: Dual therapy with anti-TIM-3 antibody + SRS or anti-TIM-3 + anti-PD-1 improved survival compared with anti-TIM-3 antibody alone. Triple therapy resulted in 100% overall survival (P < 0.05), a significant improvement compared with other arms. Long-term survivors demonstrated increased immune cell infiltration and activity and immune memory. Finally, positive staining for TIM-3 was detected in 7 of 8 human GBM samples. Conclusions: This is the first preclinical investigation on the effects of dual PD-1 and TIM-3 blockade with radiation. We also demonstrate the presence of TIM-3 in human glioblastoma multiforme and provide preclinical evidence for a novel treatment combination that can potentially result in long-term glioma survival and constitutes a novel immunotherapeutic strategy for the treatment of glioblastoma multiforme.",
author = "Kim, {Jennifer E.} and Patel, {Mira A.} and Antonella Mangraviti and Kim, {Eileen S.} and Debebe Theodros and Esteban Velarde and Ann Liu and Sankey, {Eric W.} and Ada Tam and Haiying Xu and Dimitrios Mathios and Jackson, {Christopher M.} and Sarah Harris-Bookman and Tomas Garzon-Muvdi and Mary Sheu and Martin, {Allison M.} and Tyler, {Betty M.} and Tran, {Phuoc T.} and Xiaobu Ye and Alessandro Olivi and Taube, {Janis M.} and Burger, {Peter C.} and Drake, {Charles G.} and Henry Brem and Pardoll, {Drew M.} and Michael Lim",
year = "2017",
month = "1",
doi = "10.1158/1078-0432.CCR-15-1535",
volume = "23",
pages = "124--136",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "1",

}

TY - JOUR

T1 - Combination therapy with anti-PD-1, anti-TIM-3, and focal radiation results in regression of murine gliomas

AU - Kim,Jennifer E.

AU - Patel,Mira A.

AU - Mangraviti,Antonella

AU - Kim,Eileen S.

AU - Theodros,Debebe

AU - Velarde,Esteban

AU - Liu,Ann

AU - Sankey,Eric W.

AU - Tam,Ada

AU - Xu,Haiying

AU - Mathios,Dimitrios

AU - Jackson,Christopher M.

AU - Harris-Bookman,Sarah

AU - Garzon-Muvdi,Tomas

AU - Sheu,Mary

AU - Martin,Allison M.

AU - Tyler,Betty M.

AU - Tran,Phuoc T.

AU - Ye,Xiaobu

AU - Olivi,Alessandro

AU - Taube,Janis M.

AU - Burger,Peter C.

AU - Drake,Charles G.

AU - Brem,Henry

AU - Pardoll,Drew M.

AU - Lim,Michael

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Purpose: Checkpoint molecules like programmed death-1 (PD-1) and T-cell immunoglobulin mucin-3 (TIM-3) are negative immune regulators that may be upregulated in the setting of glioblastoma multiforme. Combined PD-1 blockade and stereotactic radiosurgery (SRS) have been shown to improve antitumor immunity and produce long-term survivors in a murine glioma model. However, tumor-infiltrating lymphocytes (TIL) can express multiple checkpoints, and expression of ≥2 checkpoints corresponds to a more exhausted T-cell phenotype. We investigate TIM-3 expression in a glioma model and the antitumor efficacy of TIM-3 blockade alone and in combination with anti-PD-1 and SRS. Experimental Design: C57BL/6 mice were implanted with murine glioma cell line GL261-luc2 and randomized into 8 treatment arms: (i) control, (ii) SRS, (iii) anti-PD-1 antibody, (iv) anti-TIM-3 antibody, (v) anti-PD-1 + SRS, (vi) anti-TIM-3 + SRS, (vii) anti-PD-1 + anti-TIM-3, and (viii) anti-PD-1 + anti-TIM-3 + SRS. Survival and immune activation were assessed. Results: Dual therapy with anti-TIM-3 antibody + SRS or anti-TIM-3 + anti-PD-1 improved survival compared with anti-TIM-3 antibody alone. Triple therapy resulted in 100% overall survival (P < 0.05), a significant improvement compared with other arms. Long-term survivors demonstrated increased immune cell infiltration and activity and immune memory. Finally, positive staining for TIM-3 was detected in 7 of 8 human GBM samples. Conclusions: This is the first preclinical investigation on the effects of dual PD-1 and TIM-3 blockade with radiation. We also demonstrate the presence of TIM-3 in human glioblastoma multiforme and provide preclinical evidence for a novel treatment combination that can potentially result in long-term glioma survival and constitutes a novel immunotherapeutic strategy for the treatment of glioblastoma multiforme.

AB - Purpose: Checkpoint molecules like programmed death-1 (PD-1) and T-cell immunoglobulin mucin-3 (TIM-3) are negative immune regulators that may be upregulated in the setting of glioblastoma multiforme. Combined PD-1 blockade and stereotactic radiosurgery (SRS) have been shown to improve antitumor immunity and produce long-term survivors in a murine glioma model. However, tumor-infiltrating lymphocytes (TIL) can express multiple checkpoints, and expression of ≥2 checkpoints corresponds to a more exhausted T-cell phenotype. We investigate TIM-3 expression in a glioma model and the antitumor efficacy of TIM-3 blockade alone and in combination with anti-PD-1 and SRS. Experimental Design: C57BL/6 mice were implanted with murine glioma cell line GL261-luc2 and randomized into 8 treatment arms: (i) control, (ii) SRS, (iii) anti-PD-1 antibody, (iv) anti-TIM-3 antibody, (v) anti-PD-1 + SRS, (vi) anti-TIM-3 + SRS, (vii) anti-PD-1 + anti-TIM-3, and (viii) anti-PD-1 + anti-TIM-3 + SRS. Survival and immune activation were assessed. Results: Dual therapy with anti-TIM-3 antibody + SRS or anti-TIM-3 + anti-PD-1 improved survival compared with anti-TIM-3 antibody alone. Triple therapy resulted in 100% overall survival (P < 0.05), a significant improvement compared with other arms. Long-term survivors demonstrated increased immune cell infiltration and activity and immune memory. Finally, positive staining for TIM-3 was detected in 7 of 8 human GBM samples. Conclusions: This is the first preclinical investigation on the effects of dual PD-1 and TIM-3 blockade with radiation. We also demonstrate the presence of TIM-3 in human glioblastoma multiforme and provide preclinical evidence for a novel treatment combination that can potentially result in long-term glioma survival and constitutes a novel immunotherapeutic strategy for the treatment of glioblastoma multiforme.

UR - http://www.scopus.com/inward/record.url?scp=85010297255&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85010297255&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-15-1535

DO - 10.1158/1078-0432.CCR-15-1535

M3 - Article

VL - 23

SP - 124

EP - 136

JO - Clinical Cancer Research

T2 - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 1

ER -